/
DCF Valuation
Base-case fair value
$191.92
Intrinsic $255.89 · 25% MOS
Base-case summary
Our base-case DCF for Haemonetics Corp (HAE) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 28.0% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $260M in trailing free cash flow, this produces an intrinsic value of $255.89 per share. A 25% safety margin gives a fair value of $191.92.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$260M
Cash & equivalents
$245M
Total debt
$1.3B
Shares outstanding
47M